{
  "name" : "dacemirror.sci-hub.se_journal-article_f6fa588008fc5774d83d949960176eda_dong2016.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Poly(glycoamidoamine) brushes formulated nanomaterials for systemic siRNA and mRNA delivery in vivo",
    "authors" : [ "Yizhou Dong", "J. Robert Dorkin", "Weiheng Wang", "Philip H Chang", "Matthew J Webber", "Benjamin C Tang", "Junghoon Yang", "Inbal Abutbul-Ionita", "Dganit Danino", "Frank DeRosa", "Michael Heartlein", "Robert Langer", "Daniel G. Anderson", "Philip H. Chang", "Benjamin C. Tang" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "Subscriber access provided by GAZI UNIV\nNano Letters is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.\nCommunication\nPoly(glycoamidoamine) brushes formulated nanomaterials for systemic siRNA and mRNA delivery in vivo\nYizhou Dong, J. Robert Dorkin, Weiheng Wang, Philip H Chang, Matthew J Webber, Benjamin C Tang, Junghoon Yang, Inbal Abutbul-Ionita, Dganit Danino,\nFrank DeRosa, Michael Heartlein, Robert Langer, and Daniel G. Anderson Nano Lett., Just Accepted Manuscript • DOI: 10.1021/acs.nanolett.5b02428 • Publication Date (Web): 04 Jan 2016\nDownloaded from http://pubs.acs.org on January 9, 2016\nJust Accepted\n“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.\n1\n1 Poly(glycoamidoamine) brushes formulated nanomaterials for systemic siRNA and mRNA 2 delivery in vivo 3 4 5 Yizhou Dong,†,ǂ,§,1 J. Robert Dorkin,ǁ,1 Weiheng Wang,†,§ Philip H. Chang,†,§ Matthew J. 6 Webber,†,§ Benjamin C. Tang,†,§ Junghoon Yang,† Inbal Abutbul-Ionita,¶ Dganit Danino,¶ Frank 7 DeRosa,┴ Michael Heartlein,┴ Robert Langer,†,ǂ,§,≠ and Daniel G. Anderson†,ǂ,§,≠,* 8\n9 10 11 †David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 12 Cambridge, Massachusetts 02139, USA, ǂDepartment of Chemical Engineering, Massachusetts 13 Institute of Technology, Cambridge, Massachusetts 02139, USA, ǁDepartment of Biology, 14 Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA, §Department 15 of Anesthesiology, Children’s Hospital Boston, Harvard Medical School, Boston, MA 02115, 16 USA, ¶Department of Biotechnology and Food Engineering, Technion Institute of Technology 17 and the Russell Berrie Nanotechnology Institute, Haifa, 32000, Israel, ┴Shire, 300 Shire Way, 18 Lexington, MA 02421, USA, ≠Institute for Medical Engineering and Science, Massachusetts 19 Institute of Technology, Cambridge, Massachusetts 02139, USA. 20\n21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46\nPage 1 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n2\n1\nABSTRACT 2\n3\nSafe and effective delivery is required for siRNA and mRNA-based therapeutics to reach their 4\npotential. Here, we report on the development of poly(glycoamidoamine) brush nanoparticles as 5\ndelivery vehicles for siRNA and mRNA. These polymers were capable of significant delivery of 6\nsiRNA against FVII and mRNA-encoding erythropoietin (EPO) in mice. Importantly, these 7\nnanoparticles were well-tolerated at their effective dose based on analysis of tissue histology, 8\nsystemic cytokine levels, and liver enzyme chemistry. The polymer brush nanoparticles reported 9\nhere are promising for therapeutic applications. 10\n11\nKEYWORDS: siRNA, mRNA, polymer brush, erythropoietin, nanomaterial 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40\nPage 2 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n3\nThere is a growing interest in use of RNA, including small interfering RNA (siRNA) and 1 messenger RNA (mRNA), as therapeutics.1-8 siRNA can be used to downregulate target genes 2 while mRNA can elicit the expression of an encoded protein.9-13 siRNA and mRNA can therefore 3 also serve as useful tools to study signaling pathways,14-16 in addition to their therapeutic 4 applications.7, 17 The efficient delivery of siRNA or mRNA remains the key challenge for broad 5 applications of RNA based therapeutics in vivo.6 Lipid and polymer nanoparticles have 6 previously demonstrated efficient delivery of siRNA and mRNA,18-20 and some successful 7 examples for siRNA delivery have advanced to clinical trials to treat diverse diseases.2, 7, 8, 17 8\nHowever, delivery of siRNA and mRNA using the same materials has not been reported to date, 9\nand the combination of siRNA and mRNA may provide more effective tools for biological studies 10\nand clinical applications. 11\nHere we report on the development of a new class of polymer-brush materials (Figure 1a) 12\nfor siRNA and mRNA delivery, with subsequent evaluation of their delivery efficiency in vivo as 13\nwell as a preliminary assessment of their safety profile. To facilitate interaction with siRNA or 14\nmRNA, amino groups were incorporated into the polymer for electrostatic complexation and 15\nentrapment of negatively-charged siRNA or mRNA. In addition, multiple hydroxyl groups on the 16\npolymer increase hydrophilicity, while alkyl tail brushes added along the polymer backbone 17\nenable incorporation of the polymer brush materials into lipid-based nanoparticle formulations. 18\nThis modular design offers the ability to tune the RNA delivery system through modification of a 19\nnumber of chemical and structural properties. 20\n21\nPage 3 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n4\n1\nFigure 1. Polymer-brush materials for siRNA and mRNA delivery. a) Illustration of particle 2\nformulation with cholesterol, helper lipid, mPEG2000-DMG, and siRNA/mRNA via a microfluidic 3\nbased mixing device and evaluation through intravenous delivery. b) Synthesis of polymer-brush 4\nmaterials through ring opening reactions between poly(glycoamidoamine) (PGAAs) and 5\nepoxides, along with a representative structure (TarN3C10). TarN, GalN, and GluN were 6\nsynthesized using the methods reported by Reineke (TarN1: m=12; TarN2: m=11; TarN3: m=11; 7 GalN1: m=11; GalN2: m=14; GalN3: m=14; GluN1: m=11; GluN2: m=11; GluN3: m=11).21-24 8 1HNMR of PGAA polymers is consistent with reported data.21, 24 9\n10\nReineke and co-workers previously reported on the development of poly(glycoamidoamines) 11 (PGAAs), which contain amines and multiple hydroxyl groups along their polymer backbone.21-23, 12\nPage 4 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n5\n25, 26 These polymers previously demonstrated efficient delivery of both DNA and siRNA in 1 different cell types.21-23, 25, 26 Beginning with the PGAA polymer backbone,18, 26, 27 we prepared 2\nmodified PGAAs to create new polymer-brush materials (Figure 1b) for incorporation into lipid 3\nnanoparticle formulations. First, we synthesized three different PGAA polymers based on 4\ntartarate, galactarate, or glucarate sugars combined with three different amine-containing 5 monomers using the synthetic methods reported by Reineke.21-24 1H-NMR of PGAA polymers is 6 consistent with reported data.21-23, 25, 26 Next, alkyl tails were added to amines on the PGAA 7\nbackbone using ring-opening reactions with epoxides to afford modified polymer-brush 8 materials.27-30 In total, 31 new polymers were synthesized. Structures of polymers were 9 confirmed by 1H-NMR and their molecular weight was calculated based on the results reported 10 by Reineke and 1H-NMR of final products.22 The nomenclature for polymer identification 11\nsignifies the combination of these three structural building blocks; a three letter code(Tar- 12\ntartarate, Gal- galactarate, or Glu- glucarate) denoting the sugar used to prepare the PGAA 13\nbackbone followed by the number of amines in the amine-containing monomer (N1, N2, or N3), 14\nand finally the number of carbons (C10, C12, C14, or C16) on the epoxides used for 15\nmodification. 16\nTo formulate polymer-siRNA nanoparticles, we first mixed polymers with siRNA without 17\nadding additional components. However, the resulting complexation produces particles which 18\nare too large to be suitable for in vivo evaluation. For example, the formulated mixture of 19\nTarN3C1 with siRNA produces particles 831 nm in diameter (Table S1 in Supporting 20\nInformation). In order reduce particle size and improve polydispersity, we incorporated 21 additional formulation components based on previous experience in siRNA delivery.29 The 22\npolymer brush materials were subsequently formulated into nanoparticles through combination 23\nwith cholesterol, DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), mPEG2000-DMG (1,2-24\ndimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000]), and 25 siRNA using a microfluidic mixing device.31 To evaluate the delivery efficiency of these polymer-26\nPage 5 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n6\nbrush nanoparticles, siRNA against factor VII (FVII) was incorporated into the formulations. FVII 1\nis a blood clotting factor, which is a commonly used reporter for evaluation of siRNA delivery 2\ndue to ease of sampling. We measured the particle size using the dynamic light scattering, 3\nwhich demonstrated particles between 68 and 137 nm in diameter (Table S1 in Supporting 4\nInformation). Additionally, the siRNA loading efficiency was measured using the RiboGreen 5 assay (Table S1 in Supporting Information)18. Polymer-brush nanoparticles were administered 6\nintravenously via tail vein in mice using a FVII siRNA dose of 0.3 mg/kg. 24 hours following 7\ninjection, blood was collected and FVII levels were measured by a chromogenic assay. In sum, 8\n14 out the 31 polymers evaluated showed FVII silencing of 50% or more. We then performed a 9\ndose-dependency study of the best polymer nanoparticles at the siRNA dose of 0.3, 0.1, 0.03 10\nmg/kg (Figure 2a). As shown in Figure 2b, all of these polymer nanoparticles displayed dose-11\ndependent silencing of FVII. TarN3C10 nanoparticles silenced over 70% of FVII at a dose of 0.1 12\nmg/kg. 13\n14\nPage 6 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n7\n1\nFigure 2. siRNA delivery efficiency of polymer-brush nanoparticles. a) Silencing of FVII in 2\nmouse serum for nanoparticles at siRNA dose of 0.3 mg/kg. Control: free mRNA. b) A dose-3\ndependence study of lead materials. Lead materials showed dose-dependent silencing of FVII. 4\nC12-200 as a positive control. Data shown is mean ± s.d. (n=3). 5\n6\nTo evaluate the mRNA delivery efficiency of these polymer-brush nanoparticles, mRNA for 7\nhuman erythropoietin (EPO) was incorporated into the formulations. EPO functions to regulate 8 red blood cell production,13 and is used therapeutically by patients with anemia and 9 myelodysplasia.32 The polymer brush materials were subsequently formulated into nanoparticles 10 as previously described.31 The mRNA loading efficiency, measured by the RiboGreen assay,18 11\nwas as high as 81% for these formulations. Polymer-brush nanoparticles were administered 12\nintravenously via tail vein in mice using an EPO mRNA dose of 0.3 mg/kg, with free mRNA as a 13\nPage 7 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n8\ncontrol. Protein expression with mRNA delivery is known to peak around five to seven hours.11 1\nTherefore, six hours following injection, blood was collected and EPO levels were measured by 2\nELISA, with several polymer-brush nanoparticles demonstrating efficacy in the delivery of 3\nfunctional EPO mRNA (Figure 3a). TarN3C10 nanoparticles were further characterized using 4 cryogenic transmission electron microscopy.33-35 The TarN3C10 and TarN3C10-siRNA 5\nnanoparticles form round spherical particles. The addition of mRNA (Figure 3b, c, and d) results 6\nin the formation of more complex structures. The molecular weight difference between siRNA 7\nand mRNA could contribute to changing the particle formulation and structure. 8\nIn sum, the results presented in Figure 2 and 3 confirm that members of each of the three 9\npolymer building blocks were able to facilitate at least some delivery of siRNA and mRNA. No 10\ncorrelation was found between delivery efficiency and particle size/RNA entrapment (Figure S1 11\nin Supporting Information), while significant correlation between siRNA and mRNA delivery was 12\nobserved (Figure 3e, p< 0.0001). We also summarized several structure-activity relationship 13\nfrom these data. First, if the sugar unit and alkyl tails remain constant, efficiency increases as 14\nthe number of amino groups is increased (N1<N2<N3; e.g. TarN1C10 vs TarN2C10 vs 15\nTarN3C10; GalN2C10 vs GalN3C10; GluN2C10 vs GluN3C10, Figure 2 and 3). Second, when 16\nevaluating the significance of the sugar alone, the tartarate series was generally more efficient 17\nthan either the galactarate or glucarate series (e.g. TarN2C10 vs GalN2C10 vs GluN2C10; 18\nTarN3C10 vs GalN3C10 vs TarN3C10, Figure 2 and 3), while the galactarate series 19\ndemonstrated similar or better efficiency when compared to the glucarate series (e.g. GalN2C10 20\nvs GluN2C10; GalN3C10 vs TarN3C10, Figure 2 and 3). Taken together, the results for the 21\nimportance of sugar indicate that the number of hydroxyl groups is important to delivery 22\nefficiency. Third, when comparing polymer-brush materials on the basis of alkyl tail length, in 23\ngeneral materials with shorter tails showed better efficiency than those with longer tails 24\n(C10>C12>C14>C16, e.g. TarN1C10 vs TarN1C12 vs TarN1C14 vs TarN1C16; TarN2C10 vs 25\nTarN2C12 vs TarN2C14 vs TarN2C16; TarN3C10 vs TarN3C12 vs TarN3C14 vs TarN3C16). In 26\nPage 8 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n9\nsummation, under the current formulation methods, we can arrive at several guidelines for 1\nstructure-activity relationships: (1) efficiency is increased as then number of amino groups is 2\nincreased (N3>N2>N1); (2) the tartarate sugar improves efficiency relative to the galactarate or 3\nglucarate sugar; and (3) shorter alkyl tails improve efficiency (C10>C12>C14>C16). Consistent 4\nwith these guidelines, TarN3C10 was therefore found to be the best-performing material. 5\nTarN3C10 induced EPO expression that resulted in serum EPO concentrations of 1080 ng/mL 6\nat a dose of 0.3 mg/kg, which is much higher than C12-200 LLNs, a previously reported lipid-like 7\nnanoparticle. This was over one thousand-fold higher than expression following delivery of free 8\nEPO mRNA. 9\n10\n11\nFigure 3. mRNA delivery efficiency of polymer-brush nanoparticles. a) Expression of EPO in 12\nmouse serum for nanoparticles at mRNA dose of 0.3 mg/kg. C12-200 as a positive control. Data 13\nshown is mean ± s.d. (n=3). TarN3C10 nanoparticles demonstrated EPO expression over one 14\nPage 9 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n10\nthousand fold higher than free mRNA. Data shown is mean ± s.d. (n=3). b) Cryo-TEM of 1\nTarN3C10 without RNA. c) siRNA formulated TarN3C10 and d) mRNA formulated TarN3C10. 2\nThe TarN3C10 nanoparticles form round spherical objects with/without siRNA, and the addition 3\nof mRNA leads to formation of more complex structures. Scale bar is 100 nm for all cryo-TEM 4\nimages. e) Correlation analysis for siRNA and mRNA delivery (p< 0.0001). 5\n6\nWe next evaluated the biodistribution of the best-performing material by formulating 7\nTarN3C10 with luciferase mRNA. In these studies, TarN3C10 nanoparticles were injected 8\nintravenously at an mRNA dose of 1 mg/kg. Through luminescence imaging, we measured 9\nsignal arising from the pancreas, liver, spleen, kidneys, uterus/ovaries, fat, muscle, lungs, heart, 10\nand thymus (Figure S2 in Supporting Information). Luciferase expression following mRNA 11\ndelivery with TarN3C10 nanoparticles was over one thousand-fold higher in the liver and spleen 12\ncompared to the administration of free mRNA, normalized by tissue weight. Additionally, over 13\nten-fold higher luciferase expression was detected in the pancreas, uterus/ovaries, fat, kidneys, 14\nmuscle, lungs, heart, and thymus for TarN3C10-treated animals relative to the free mRNA 15\ncontrol. 16\nIn addition to delivery efficiency, the clinical use of RNA therapeutics requires an acceptable 17 safety profile.36 A preliminary single dose toxicity study of TarN3C10 nanoparticles was 18\nconducted, followed by histopathology, a serum cytokine panel, and liver blood chemistry in 19\nmice dosed at 1 mg/kg siRNA. Tissue and blood samples were collected at 24 and 48 hours 20\nafter injection. No histological abnormalities were observed in liver, spleen, kidney, heart, or 21\nlung at either time point (Figure 4). We also analyzed a panel of 31 different cytokines in serum. 22\nWe detected a transient increase in expression of G-CSF and MIG at 24 hr in the treated groups 23\ncompared with control groups, and this increase returned to baseline at 48 hr (Figure S3 in 24\nSupporting Information). Finally, we analyzed serum chemistry for alanine transaminase (ALT), 25\naspartate transaminase (AST), and total bilirubin of TarN3C10-treated animals in comparison to 26\nPage 10 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n11\ncontrols (Table S2 in Supporting Information), and no significant differences were observed. 1\nTaken together, this preliminary single dose toxicity study supports a conclusion that TarN3C10 2\nnanoparticles are well tolerated in mice at these doses. Detailed toxicity studies are ongoing 3\nand will be reported in due course. 4\n5\n6\nFigure 4. Histology images of liver, spleen, kidney, heart, and lung (Scale bar= 50 um). PBS 7\ncontrol, TarN3C10-treated group at 24h, and TarN3C10-treated group at 48h. No histological 8\nabnormalities were observed in the treated group at either time. 9\nWe have described the synthesis and evaluation of novel polymer-brush nanoparticles for 10\nsiRNA and mRNA delivery. A modular design strategy enabled the creation of 31 new polymers 11\nwith building blocks consisting of amino groups, multiple hydroxyl groups, and alkyl tails. 12\nAnalyzing structure-activity relationships indicates that all three building blocks contribute to 13\nefficient mRNA encapsulation and delivery. The key structural features of top performing 14\nformulations revealed that more amino groups are favorable, the tartarate series is in general 15\nmore potent than the galactarate or glucarate series, and shorter alkyl tails improve 16\nperformance. These guidelines can be used to inform the design of next-generation RNA 17\ndelivery systems. Importantly, we found significant correlation for siRNA and mRNA delivery. Of 18\nPage 11 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n12\ninterest, we note that human patients with chemotherapy-related anemia receive EPO at 40,000 1 units/week, translating to approximately 308 ug.37 Our lead polymeric nanoparticle reported here, 2\nTarN3C10, induced EPO expression of 1080ng/mL with an mRNA dose of 0.3 mg/kg. This 3\nwould translate to a dose roughly 10-fold higher than that used clinically for EPO. Finally, a 4\nsingle dose toxicity study revealed TarN3C10 nanoparticles are well tolerated based on 5\nhistopathology, broad panel cytokine screening, and liver blood chemistry profiles. As such, 6\nstrategies based on the platform of polymer-brush nanoparticles reported here may have 7\npromise for use in RNA-based therapy. 8\n9\nMethods 10\nMaterials. 11\nCholesterol was purchased from Sigma Aldrich; DSPC (1,2-distearoyl-sn-glycero-3-12\nphosphocholine), were purchased from Avanti Polar Lipids, and mPEG2000-DMG (1,2-13\ndimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] were 14\nprovided by Alnylam. Slide-A-Lyzer dialysis cassettes were obtained from Pierce Thermo 15 Scientific. The microfluidics devices were made as previously published.31 The RiboGreen was 16\nordered from Invitrogen Life Technologies, and used as according to the manufacturer 17\nguidelines. The EPO and luciferase mRNA used were generously provided by Shire. Serum 18\nseparator tubes were purchased from BD biosciences. The EPO ELISA kits were from R&D 19\nSystems Inc. 20"
    }, {
      "heading" : "General Procedures for Synthesis of Polymer Brush Materials. 21",
      "text" : "Poly(glycoamidoamine) (PGAA) was synthesized according to synthetic methods reported by 22 Reineke.21 Polymer structures were confirmed with 1HNMR. PGAAs undergo ring opening 23\nreactions with diverse epoxides to afford the desired polymer brush materials. A mixture of 24\nPGAA and epoxides (a ratio of 1.5:1 epoxides/ amine) in EtOH was irradiated in a microwave 25\nPage 12 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n13\noven at 140 oC for 5 h. The reaction mixture was purified by flash chromatography using a 1\nsolvent system CH2Cl2:MeOH:NH4OHaq 87.5∶11∶1.5. 2"
    }, {
      "heading" : "Formulation Procedure. 3",
      "text" : "Liposomes were formed using a microfluidics devices, as previously described.31 Briefly, the 4\npolymer brush, DSPC, cholesterol, and mPEG2000-DMG were dissolved in ethanol and 5\ncombined in a 5:2:2:1 weight ratio. The siRNA/mRNA was dissolved in a 10mM citrate buffer, 6\npH=3.0. The polymer : siRNA/mRNA weight ratio was 5:1 and 10:1, respectively. The ethanol 7\nand aqueous solutions were combined in a 1:1 ratio using the microfluidics device, and 8\nimmediately diluted two-fold in PBS. Formulations were then dialyzed against PBS dialysis 9\ncassettes. The relative mRNA entrapment was determined using a RiboGreen fluorescent 10\nassay and the volume mean particle diameter was determined via dynamic light scattering 11\n(ZetaPALS, Brookhaven Instruments). 12"
    }, {
      "heading" : "Cryo-Transmission Electron Microscopy (cryo-TEM). 13",
      "text" : "Cryo-TEM samples are prepared in a controlled environment vitrification system (CEVS) or 14\nusing the commercial environmentally controlled automated Vitrobot (FEI, Netherlands), always 15\nat a controlled temperature (25 °C) and at saturation. A 6 µl drop of the suspension is placed on 16\na 400-mesh TEM copper grid covered with a perforated carbon film. To remove excess solution 17\nand produce a thin liquid film the drop is blotted - manually in the CEVS and automatically in the 18\nVitrobot. The blotted sample is then plunged into liquid ethane (−183 °C) to form a vitrified 19\nspecimen and transferred to liquid nitrogen (–196°C) for storage. Vitrified specimens are 20\nexamined at temperatures below −175 °C using a Gatan 626 cryo holder either in a Tecnai T12 21\nG2 TEM (FEI, Netherlands) or a Philips CM120 TEM operating at 120 kV. Images are recorded 22\non a Gatan MultiScan 791 camera or Gatan UltraScan 1000 using the DigitalMicrograph 23\nsoftware (Gatan, U.K.) in the low-dose imaging mode to minimize beam exposure and electron-24 beam radiation damage, as described.35, 38 25\nPage 13 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n14\nPreparation of FFL and human EPO messenger RNA. 1\nFirefly Luciferase (FFL) and human erythropoietin (hEPO) messenger RNA were synthesized 2\nvia in vitro transcription from a plasmid DNA template encoding the respective gene. The 3\nsubsequent transcript was further reacted by the enzymatic addition of a 5’ cap structure (Cap 1) 4\nand a 3’ poly (A) tail of approximately 300 nucleotides in length as determined by gel 5 electrophoresis.39 The messenger RNA was purified using commercially available silica-based 6\nspin column technology. 7\nIn Vivo Factor VII Silencing. All procedures used in animal studies conducted at MIT and 8\nAlnylam were approved by the Institutional Animal Care and Use Committee (IACUC) and were 9\nalso consistent with local, state and federal regulations as applicable. C57BL/6 mice were 10\nadministered intravenously via tail vein injection for siRNA silencing experiments. After 24 h, 11\nanimals were anaesthetized by isofluorane inhalation for blood sample collection by retroorbital 12\neye bleed using serum separation tubes. Protein levels of Factor VII were calculated by 13\nchromogenic assay (Biophen FVII, Aniara Corporation) with a standard curve obtained from 14\ncontrol mice. 15\nIn Vivo EPO mRNA Delivery in Mice. 16\nAll procedures used in animal studies conducted at MIT were approved by the Institutional 17\nAnimal Care and Use Committee (IACUC) and were also consistent with local, state and federal 18\nregulations as applicable. Formulated mRNA was administered intravenously via tail vein 19\ninjection using C57BL/6 mice (Charles River Labs, 6 to 8 weeks old, 18-22 grams) were for 20\nmRNA expression experiments. After 6 h, blood was collected from the mice via the tail vein, 21\nand serum was obtained using serum separation tubes. EPO levels were measured by an 22\nELISA assay using standard EPO protein. 23\nBiodistribution of TarN3C10-mRNA Nanopartilces in Mice. 24\nPage 14 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n15\nC57BL/6 mice were administered intravenously via tail vein injection for luciferase mRNA 1\nexpression experiments. The mice were sacrificed 24 hours post injection; the pancreas, spleen, 2\nliver, kidneys, ovaries/uterus, heart, lungs, and thymus as well as a section of the adipose tissue 3\nand muscle tissue were then dissected. The tissues were examined with an IVIS imaging 4\nsystem from Caliper. Signal strength of the individual tissue was normalized against tissue 5\nweight. 6"
    }, {
      "heading" : "Toxicity study in mice. 7",
      "text" : "C57Bl/6 mice were administered intravenously TarN3C10 nanoparticles via tail vein injection. 8\nBlood and tissue samples were collected 24 and 48 hours after injection from the animals. 9\nHistopathology on liver, spleen, kidneys, heart, and lungs were processed and evaluated by the 10\nhistology core facility of Koch Institute. Immunoassays were used to measure the levels of 11\ncytokines in a 96-well plate using Bio-Plex Pro™ assays formatted on magnetic beads. 30 12\ndifferent cytokines were analyzed: IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12 13\n(p70), IL-13, IL-17, Exotaxin, G-CSF, GM-CSF, IFN-γ, KC, MCP-1, MIP-1a, MIP-1b, RANTES, 14\nTNG-α, IL-18, FGF-basic, LIF, M-CSF, MIG, MIP-2, PDGF-bb and VEGF. Clinical chemistry of 15\nALT, AST, and total bilirubin were measured by IDEXX Laboratories. 16\n17"
    }, {
      "heading" : "ASSOCIATED CONTENT 18",
      "text" : "Supporting Information Available: The experimental methods and supplementary figures. This 19\nmaterial is available free of charge via the Internet at http://pubs.acs.org. 20\n21\nAUTHOR INFORMATION 22\nCorresponding Author *E-mail: dgander@mit.edu. 1: Y.D. and J.R.D. contributed equally to the 23\npaper. Y.D. present address: Division of Pharmaceutics & Pharmaceutical Chemistry, College of 24\nPharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, Ohio 43210, USA, 25\nPage 15 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n16\nThe authors declare no competing financial interest. 1\n2\nACKNOWLEDGEMENTS 3\nThe authors thank the Koch Institute Swanson Biotechnology Center for technical support, 4\nspecifically Animal Imaging and Histology Core. This work was supported by the National 5\nCancer Institute Center of Cancer Nanotechnology Excellence at MIT-Harvard (U54-CA151884), 6\nthe National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), as a Program 7\nof Excellence in Nanotechnology (PEN) Award, Contract #HHSN268201000045C, as well as by 8\nShire, Alnylam Pharmaceuticals, and the NIH Grants R01-EB000244–27, 5-R01-CA132091–04, 9\nand R01-DE016516–03. Y.D. acknowledges support from the National Institute of Biomedical 10\nImaging and Bioengineering for his postdoctoral fellowship 1F32EB017625. 11\n12 REFERENCES 13 14 1. Tavernier, G.; Andries, O.; Demeester, J.; Sanders, N. N.; De Smedt, S. C.; Rejman, J. J 15 Control Release 2011, 150, (3), 238-247. 16 2. Pascolo, S. Handb Exp Pharmacol 2008, (183), 221-235. 17 3. Sahin, U.; Kariko, K.; Tureci, O. Nat Rev Drug Discov 2014, 13, (10), 759-780. 18 4. McIvor, R. S. Mol Ther 2011, 19, (5), 822-823. 19 5. Weissman, D.; Kariko, K. Mol Ther 2015, 23, (9), 1416-7. 20 6. Whitehead, K. A.; Langer, R.; Anderson, D. G. Nature Reviews Drug Discovery 2009, 8, 21 (2), 129-138. 22 7. Burnett, J. C.; Rossi, J. J.; Tiemann, K. Biotechnol J 2011, 6, (9), 1130-46. 23 8. de Fougerolles, A.; Vornlocher, H. P.; Maraganore, J.; Lieberman, J. Nat Rev Drug 24 Discov 2007, 6, (6), 443-53. 25 9. Kariko, K.; Muramatsu, H.; Keller, J. M.; Weissman, D. Mol Ther 2012, 20, (5), 948-953. 26 10. Kariko, K.; Muramatsu, H.; Welsh, F. A.; Ludwig, J.; Kato, H.; Akira, S.; Weissman, D. 27 Molecular Therapy 2008, 16, (11), 1833-1840. 28 11. Phua, K. K.; Leong, K. W.; Nair, S. K. J Control Release 2013, 166, (3), 227-233. 29 12. Zangi, L.; Lui, K. O.; von Gise, A.; Ma, Q.; Ebina, W.; Ptaszek, L. M.; Spater, D.; Xu, H.; 30 Tabebordbar, M.; Gorbatov, R.; Sena, B.; Nahrendorf, M.; Briscoe, D. M.; Li, R. A.; Wagers, A. 31 J.; Rossi, D. J.; Pu, W. T.; Chien, K. R. Nat Biotechnol 2013, 31, 898–907. 32 13. Kormann, M. S.; Hasenpusch, G.; Aneja, M. K.; Nica, G.; Flemmer, A. W.; Herber-Jonat, 33 S.; Huppmann, M.; Mays, L. E.; Illenyi, M.; Schams, A.; Griese, M.; Bittmann, I.; Handgretinger, 34 R.; Hartl, D.; Rosenecker, J.; Rudolph, C. Nat Biotechnol 2011, 29, (2), 154-157. 35 14. Kariko, K.; Ni, H. P.; Capodici, J.; Lamphier, M.; Weissman, D. Journal of Biological 36 Chemistry 2004, 279, (13), 12542-12550. 37 15. Kariko, K.; Buckstein, M.; Ni, H.; Weissman, D. Immunity 2005, 23, (2), 165-75. 38\nPage 16 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n17\n16. Sahay, G.; Querbes, W.; Alabi, C.; Eltoukhy, A.; Sarkar, S.; Zurenko, C.; Karagiannis, E.; 1 Love, K.; Chen, D.; Zoncu, R.; Buganim, Y.; Schroeder, A.; Langer, R.; Anderson, D. G. Nat 2 Biotechnol 2013, 31, (7), 653-8. 3 17. Weide, B.; Carralot, J. P.; Reese, A.; Scheel, B.; Eigentler, T. K.; Hoerr, I.; Rammensee, 4 H. G.; Garbe, C.; Pascolo, S. J Immunother 2008, 31, (2), 180-8. 5 18. Akinc, A.; Zumbuehl, A.; Goldberg, M.; Leshchiner, E. S.; Busini, V.; Hossain, N.; 6 Bacallado, S. A.; Nguyen, D. N.; Fuller, J.; Alvarez, R.; Borodovsky, A.; Borland, T.; Constien, 7 R.; de Fougerolles, A.; Dorkin, J. R.; Narayanannair Jayaprakash, K.; Jayaraman, M.; John, M.; 8 Koteliansky, V.; Manoharan, M.; Nechev, L.; Qin, J.; Racie, T.; Raitcheva, D.; Rajeev, K. G.; 9 Sah, D. W.; Soutschek, J.; Toudjarska, I.; Vornlocher, H. P.; Zimmermann, T. S.; Langer, R.; 10 Anderson, D. G. Nat Biotechnol 2008, 26, (5), 561-9. 11 19. Semple, S. C.; Akinc, A.; Chen, J.; Sandhu, A. P.; Mui, B. L.; Cho, C. K.; Sah, D. W.; 12 Stebbing, D.; Crosley, E. J.; Yaworski, E.; Hafez, I. M.; Dorkin, J. R.; Qin, J.; Lam, K.; Rajeev, K. 13 G.; Wong, K. F.; Jeffs, L. B.; Nechev, L.; Eisenhardt, M. L.; Jayaraman, M.; Kazem, M.; Maier, 14 M. A.; Srinivasulu, M.; Weinstein, M. J.; Chen, Q.; Alvarez, R.; Barros, S. A.; De, S.; Klimuk, S. 15 K.; Borland, T.; Kosovrasti, V.; Cantley, W. L.; Tam, Y. K.; Manoharan, M.; Ciufolini, M. A.; 16 Tracy, M. A.; de Fougerolles, A.; MacLachlan, I.; Cullis, P. R.; Madden, T. D.; Hope, M. J. Nat 17 Biotechnol 2010, 28, (2), 172-6. 18 20. Cheng, C.; Convertine, A. J.; Stayton, P. S.; Bryers, J. D. Biomaterials 2012, 33, (28), 19 6868-76. 20 21. Liu, Y.; Wenning, L.; Lynch, M.; Reineke, T. M. J Am Chem Soc 2004, 126, (24), 7422-3. 21 22. Liu, Y.; Reineke, T. M. Biomacromolecules 2010, 11, (2), 316-25. 22 23. McLendon, P. M.; Fichter, K. M.; Reineke, T. M. Mol Pharm 2010, 7, (3), 738-50. 23 24. Liu, Y.; Wenning, L.; Lynch, M.; Reineke, T. M. ACS Symposium Series 2006, 923, 24 (Polymeric Drug Delivery I), 217-227. 25 25. Ingle, N. P.; Malone, B.; Reineke, T. M. Trends in biotechnology 2011, 29, (9), 443-53. 26 26. Tranter, M.; Liu, Y.; He, S.; Gulick, J.; Ren, X.; Robbins, J.; Jones, W. K.; Reineke, T. M. 27 Mol Ther 2012, 20, (3), 601-8. 28 27. Love Kevin, T.; Mahon Kerry, P.; Levins Christopher, G.; Whitehead Kathryn, A.; 29 Querbes, W.; Dorkin, J. R.; Qin, J.; Cantley, W.; Qin Liu, L.; Racie, T.; Frank-Kamenetsky, M.; 30 Yip Ka, N.; Alvarez, R.; Sah Dinah, W. Y.; de Fougerolles, A.; Fitzgerald, K.; Koteliansky, V.; 31 Akinc, A.; Langer, R.; Anderson Daniel, G. Proc Natl Acad Sci U S A 2010, 107, (5), 1864-9. 32 28. Siegwart, D. J.; Whitehead, K. A.; Nuhn, L.; Sahay, G.; Cheng, H.; Jiang, S.; Ma, M.; 33 Lytton-Jean, A.; Vegas, A.; Fenton, P.; Levins, C. G.; Love, K. T.; Lee, H.; Cortez, C.; Collins, S. 34 P.; Li, Y. F.; Jang, J.; Querbes, W.; Zurenko, C.; Novobrantseva, T.; Langer, R.; Anderson, D. G. 35 Proc Natl Acad Sci U S A 2011, 108, (32), 12996-3001. 36 29. Dong, Y.; Love, K. T.; Dorkin, J. R.; Sirirungruang, S.; Zhang, Y.; Chen, D.; Bogorad, R. 37 L.; Yin, H.; Chen, Y.; Vegas, A. J.; Alabi, C. A.; Sahay, G.; Olejnik, K. T.; Wang, W.; Schroeder, 38 A.; Lytton-Jean, A. K.; Siegwart, D. J.; Akinc, A.; Barnes, C.; Barros, S. A.; Carioto, M.; 39 Fitzgerald, K.; Hettinger, J.; Kumar, V.; Novobrantseva, T. I.; Qin, J.; Querbes, W.; Koteliansky, 40 V.; Langer, R.; Anderson, D. G. Proc Natl Acad Sci U S A 2014, 111, (11), 3955-3960. 41 30. Zhang, Y.; Pelet, J. M.; Heller, D. A.; Dong, Y.; Chen, D.; Gu, Z.; Joseph, B. J.; Wallas, 42 J.; Anderson, D. G. Adv Mater 2013, 25, (33), 4641-4645. 43 31. Chen, D.; Love, K. T.; Chen, Y.; Eltoukhy, A. A.; Kastrup, C.; Sahay, G.; Jeon, A.; Dong, 44 Y.; Whitehead, K. A.; Anderson, D. G. J Am Chem Soc 2012, 134, (16), 6948-6951. 45 32. Coleman, T.; Brines, M. Crit Care 2004, 8, (5), 337-41. 46 33. Dahlman, J. E.; Barnes, C.; Khan, O. F.; Thiriot, A.; Jhunjunwala, S.; Shaw, T. E.; Xing, 47 Y.; Sager, H. B.; Sahay, G.; Speciner, L.; Bader, A.; Bogorad, R. L.; Yin, H.; Racie, T.; Dong, Y.; 48 Jiang, S.; Seedorf, D.; Dave, A.; Singh Sandhu, K.; Webber, M. J.; Novobrantseva, T.; Ruda, V. 49 M.; Lytton-Jean, A. K.; Levins, C. G.; Kalish, B.; Mudge, D. K.; Perez, M.; Abezgauz, L.; Dutta, 50 P.; Smith, L.; Charisse, K.; Kieran, M. W.; Fitzgerald, K.; Nahrendorf, M.; Danino, D.; Tuder, R. 51\nPage 17 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\n18\nM.; von Andrian, U. H.; Akinc, A.; Panigrahy, D.; Schroeder, A.; Koteliansky, V.; Langer, R.; 1 Anderson, D. G. Nat Nanotechnol 2014, 9, (8), 648-655. 2 34. Michel, R.; Kesselman, E.; Plostica, T.; Danino, D.; Gradzielski, M. Angew Chem Int Ed 3 Engl 2014, 53, 12441-12445. 4 35. Danino, D. Curr Opin Colloid In 2012, 17, (6), 316-329. 5 36. Barros, S. A.; Gollob, J. A. Adv Drug Deliv Rev 2012, 64, (15), 1730-7. 6 37. Jelkmann, W. Nephrology, dialysis, transplantation : official publication of the European 7 Dialysis and Transplant Association - European Renal Association 2009, 24, (5), 1366-8. 8 38. Danino, D.; Bernheim-Groswasser, A.; Talmon, Y. Colloid Surface A 2001, 183, 113-122. 9 39. Fechter, P.; Brownlee, G. G. The Journal of general virology 2005, 86, (Pt 5), 1239-1249. 10\n11\nPage 18 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60\nPage 19 of 19\nACS Paragon Plus Environment\nNano Letters\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60"
    } ],
    "references" : [ {
      "title" : "Trends in biotechnology",
      "author" : [ "N.P. Ingle", "B. Malone", "T.M. Reineke" ],
      "venue" : null,
      "citeRegEx" : "25",
      "shortCiteRegEx" : "25",
      "year" : 2011
    }, {
      "title" : "ACS Paragon Plus Environment Nano Letters 1 2 3 4 5 6 7 8",
      "author" : [ "J.E. Dahlman", "C. Barnes", "O.F. Khan", "A. Thiriot", "S. Jhunjunwala", "T.E. Shaw", "47 Y. Xing", "H.B. Sager", "G. Sahay", "L. Speciner", "A. Bader", "R.L. Bogorad", "H. Yin", "T. Racie", "Y. Dong", "S. 48 Jiang", "D. Seedorf", "A. Dave", "K. Singh Sandhu", "M.J. Webber", "T. Novobrantseva", "V.  49 M. Ruda", "A.K. Lytton-Jean", "C.G. Levins", "B. Kalish", "D.K. Mudge", "M. Perez", "L. Abezgauz", "50 P. Dutta", "L. Smith", "K. Charisse", "M.W. Kieran", "K. Fitzgerald", "M. Nahrendorf", "D. Danino", "R. Tuder" ],
      "venue" : "Nanotechnol 2014,",
      "citeRegEx" : "33",
      "shortCiteRegEx" : "33",
      "year" : 2014
    }, {
      "title" : "Nephrology, dialysis, transplantation : official publication of the European 7 Dialysis and Transplant Association - European Renal Association",
      "author" : [ "W. Jelkmann" ],
      "venue" : null,
      "citeRegEx" : "37",
      "shortCiteRegEx" : "37",
      "year" : 2009
    } ],
    "referenceMentions" : [ {
      "referenceID" : 1,
      "context" : "cryogenic transmission electron microscopy.(33-35) The TarN3C10 and TarN3C10-siRNA 5",
      "startOffset" : 42,
      "endOffset" : 50
    }, {
      "referenceID" : 2,
      "context" : "units/week, translating to approximately 308 ug.(37) Our lead polymeric nanoparticle reported here, 2",
      "startOffset" : 48,
      "endOffset" : 52
    } ],
    "year" : 2016,
    "abstractText" : "2",
    "creator" : null
  }
}